{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-017376","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.312769+00:00","generated_at":"2026-06-24T00:03:16.298415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ginkgo Q2 revenue $145M (+231% YoY); guides total revenue to $425-440M","bullets":["Foundry revenue $44M (+105% YoY); added 13 new Cell Programs in Q2.","Biosecurity revenue $100M with 36% gross margin; expects at least $260M for FY 2022.","Adjusted EBITDA improved to -$23M from -$38M YoY; cash balance ~$1.4B.","Pending acquisitions of Zymergen (all-stock) and Bayer's West Sacramento facility expected to close Q4 2022 / Q1 2023.","Dr. Kathy Hopinkah Hannan appointed to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-017376","json":"https://secwatch.observer/filing/0000950170-22-017376.json","markdown":"https://secwatch.observer/filing/0000950170-22-017376.md","text":"https://secwatch.observer/filing/0000950170-22-017376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022017376/0000950170-22-017376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000095017022017376/dna-20220815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:03:16.298415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}